Dashenlin Pharmaceutical shareholder's stake dips below 20%

Dashenlin Pharmaceutical Group Co., Ltd. announced that its controlling shareholder, Ke Jinlong, completed a share reduction plan on September 9, 2025. This move was intended to adjust assets, restructure financing, and reduce stock pledge rates.

Ke Jinlong decreased his holdings by 22,700,000 shares through block trades, representing 1.99% of the company's total share capital. Prior to the reduction, Ke Jinlong held 229,631,849 shares, accounting for 20.16% of the total share capital. Following the plan's completion, his stake now stands at 206,931,849 shares, or 18.17%.

The transaction value amounted to CNY 374,096,000, with prices ranging from CNY 16.48 to CNY 16.48 per share. This equity change triggered the 1% threshold, reducing the combined holdings of the controlling shareholder and concerted parties from 64.04% to 62.05%. The company confirmed this change does not involve a tender offer and will not alter the company's controlling shareholder or actual controller.